✨ Free AI Report
Sera Prognostics, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Sera Prognostics, Inc.
Company Research

Sera Prognostics, Inc.: Business Overview, Financials & Competitive Analysis

Sera Prognostics, Inc. scores 5/10 on the AskCyborg Cyborg Score (Mixed). Clinical validation through PRIME study provides strong proof-of-concept, but commercial traction and payer reimbursement execution remain uncertain in competitive diagnostics market. Sera has significant clinical validation (PRIME trial published Jan 2026 showing 20% reduction in NICU admissions) and ~$102M cash runway through 2028, but faces early commercialization stage challenges.

What is Sera Prognostics, Inc.'s industry? Sera Prognostics, Inc. (sera.com) operates in Women's Health Diagnostics / Precision Pregnancy Care / In Vitro Diagnostics (IVD). AskCyborg classifies Sera Prognostics, Inc. under Women's Health Diagnostics / Precision Pregnancy Care / In Vitro Diagnostics (IVD) in its company registry.

Sera Prognostics is a women's health diagnostic company that discovers, develops, and commercializes blood-based biomarker tests for pregnancy complications. The company's flagship product, the PreTRM test, is the onl...

5/ 10Mixed

Cyborg Score thesis

Clinical validation through PRIME study provides strong proof-of-concept, but commercial traction and payer reimbursement...

Read the full analyst-debate transcript →
Industry Women's Health Diagnostics / Precision Pregnancy Care / In Vitro Diagnostics (IVD)
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Sera Prognostics, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Sera Prognostics, Inc.

AskCyborg analysts argue the bull and bear cases for Sera Prognostics, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Sera Prognostics, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Sera Prognostics, Inc. Overview

Pro stress-test →

Sera Prognostics is a women's health diagnostic company that discovers, develops, and commercializes blood-based biomarker tests for pregnancy complications. The company's flagship product, the PreTRM test, is the only FDA-validated blood test to predict preterm birth risk, addressing a critical unmet need in prenatal care affecting millions of pregnancies annually.

Strategic Profile

Pro stress-test →

Sera leverages proprietary proteomics and bioinformatics platforms to build a pipeline of pregnancy-related biomarker tests including preeclampsia, fetal growth restriction, and gestational diabetes detection. The company is pursuing payer adoption through Medicaid pilots across multiple states while scaling from early commercialization toward market penetration in precision pregnancy care.

Competitive Landscape

Pro stress-test →

Sera competes in the pregnancy diagnostics and women's health biomarker space against companies like Biodesix, BioGenex, GRAIL, and other diagnostic developers. Sera's differentiation centers on the PreTRM test's clinical validation and first-mover advantage in preterm birth prediction, though broader adoption requires successful Medicaid reimbursement and clinical integration into standard prenatal care protocols.

Industry Context

Sera Prognostics, Inc. operates in Women's Health Diagnostics / Precision Pregnancy Care / In Vitro Diagnostics (IVD).

Key facts

Founded: 2008 · Headquarters: Salt Lake City, Utah · Revenue: $95K (TTM as of Sept 2025) · Market cap: $144.6M

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Sera Prognostics, Inc..

  • PRIME trial (5,018 women) published Jan 2026 demonstrates PreTRM test reduces earliest preterm births and neonatal complications by 20% NICU reduction
  • Early payer engagement across 13 states with active Nevada Medicaid pilot and $100K deferred revenue showing pathway to reimbursement
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • January 2026PRIME study published showing PreTRM test reduced earliest preterm births and newborn complications
  • November 2025Q3 2025 earnings: $16K revenue, $7.8M net loss, $102.4M cash position; Nevada Medicaid pilot active
  • +1 moreTrack every material event for Sera Prognostics, Inc. as it happens. Explore monitoring →
Get alerted when Sera Prognostics, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Biodesix TechnologyPrecision diagnostics for lung and blood cancers→GRAIL TestBlood-based cancer early detection→RareCyte PlatformCell analysis and diagnostic imaging→

Compare Sera Prognostics, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Sera Prognostics, Inc. operates in Women's Health Diagnostics / Precision Pregnancy Care / In Vitro Diagnostics (IVD). See how the rest of the sector scores on the Cyborg framework.

Browse Women's Health Diagnostics / Precision Pregnancy Care / In Vitro Diagnostics (IVD) research →
NEW · MCP server

Ask your AI assistant about Sera Prognostics, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Sera Prognostics, Inc. and its top competitor on Cyborg Score”
“What did Sera Prognostics, Inc. do this quarter?”
“Is Sera Prognostics, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Sera Prognostics, Inc. do?+
Sera Prognostics is a women's health diagnostic company that discovers, develops, and commercializes blood-based biomarker tests for pregnancy complications. The company's flagship product, the PreTRM test, is the onl...
What is Sera Prognostics, Inc.'s Cyborg Score?+
Sera Prognostics, Inc. has a Cyborg Score of 5/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Sera Prognostics, Inc.'s main competitors?+
Named competitors include Biodesix Technology, GRAIL Test, RareCyte Platform. The full competitive landscape is in the AskCyborg report.
How can I get the full Sera Prognostics, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Sera Prognostics, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Sera Prognostics, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.